Inactivation of SARS-CoV-2 virus in saliva using a guanidium based transport medium suitable for RT-PCR diagnostic assays

Ethical considerations

The use of saliva from confirmed COVID-19 negative volunteers was approved by Rutgers Institutional Review Board, IRB# 2020001786.

Cell and viral culture

Vero E6 cells (ATCC CRL-1586) were maintained in the Dulbecco’s Modified Eagle Medium (DMEM, Gibco, Thermo Fisher Scientific, Waltham, MA) supplemented with 10% heat-inactivated fetal bovine serum (FBS, Gibco, Thermo Fisher Scientific, Waltham, MA) and 100 units/ml of penicillin/streptomycin (Gibco, Thermo Fisher Scientific, Waltham, MA) at 37°C in the presence of 5% CO₂. SARS-CoV-2 strain USA-WA1/2020 was obtained from the World Reference Collection for Emerging Viruses and Arboviruses (WRECVA) at the University of Texas Medical Branch (UTMB, Galveston, TX) and further propagated in Biosafety level 3 (BSL3) laboratory at the Regional Biocontainment Laboratory (RBL), Rutgers New Jersey Medical School, Newark, NJ. All cell lines and virus cultures were maintained at 37°C in the presence of 5% CO₂ unless otherwise mentioned. All experiments in this study were performed inside a biosafety cabinet within a BSL3 containment facility. To generate working virus stocks, Vero E6 cells were infected with an MOI of 0.01 in DMEM supplemented with 2% FBS. Cells were harvested at 72 hours post-infection, supernatants were collected and centrifuged for 10 min at 1,000Xg, aliquoted and stored at - 80°C.

Virus quantitation

SARS-CoV-2 virus titers were determined using both plaque assays and the 50% tissue culture infectious dose (TCID50) method. Plaque assays were performed following standard procedures [14-16] with some modifications. Briefly, Vero E6 cells were seeded into 6-well plates (5×10⁵ cells/well) 24 hours before infection. Ten-fold serial dilutions of virus stock were added onto wells (400µl/well) and incubated for 1 hour at 37°C with intermittent shaking every 15 min to prevent the cell monolayers from drying. After 1 hour of virus adsorption, 4ml of 0.8% agarose in DMEM supplemented with 4% FBS was added to each well and incubated for 2-3 days at 37°C/CO₂ incubator. The plaques were developed by fixing the cells with 4% formaldehyde in PBS for 1h at room temperature (RT). The agarose plug was removed before staining with 0.2% crystal violet (in 20% ethanol for 15 min at RT). The wells were washed with tap water, dried and the plaques were counted. TCID50 assays were performed by seeding 96-well plates with Vero E6 cells (2×10⁴ cells/well) the day before the assay. Ten-fold serial dilutions of virus stock were added onto wells (100µl/well) and incubated for 7-10 days at 37°C/CO₂ incubator. The plates were observed for presence of cytopathic effect (CPE) every day. TCID50 titers were calculated using the Reed and Muench method [17].

Removal of cytotoxicity

Four different approaches were explored to remove cytotoxicity induced by the transport media in the absence of the virus. Pierce 4ml Detergent Removal Spin Column (DRSC, Thermo Fisher Scientific, Waltham, MA), Amicon Ultra 4ml 100KDa centrifugal filter units (Millipore Sigma, St. Louis, MO), PD 10 desalting spin columns (Millipore Sigma, St. Louis, MO) and Slide-A-Lyzer G2 dialysis cassette (Thermo Fisher Scientific, Waltham, MA) were prepared according to each manufacturer’s instructions. Two ml of eNAT (Copan Diagnostics, Murrieta, CA) was added to 100 µl of DMEM without the virus, mixed and then processed using each method. Both PD 10 columns and Slide-A-Lyzer G2 dialysis cassettes were equilibrated with PBS before adding samples. For the Slide-A-Lyzer G2 dialysis cassette, the 2.1 ml samples were added and the cassette was dialyzed overnight at room temperature in PBS with a total of five buffer changes. For Amicon ultra filters, the 2.1 ml samples were added, centrifuged at 4,000 x g for 10 min and washed three times with 2ml of PBS. For PD 10 columns, the 2.1 ml samples were added and the eluate was collected by centrifugation at 1000 x g for 2 min. For the Pierce DRSC columns, the 2.1 ml samples were split into two 1.05 ml samples that were each added to one of two columns, incubated for 2 min at room temperature and then eluted by centrifugation at 1000 x g for 2 min. Four hundred microliters of the samples processed by each method were then added to Vero E6 cells in 6-well plates, incubated at 37°C/CO₂ incubator and observed daily for cytotoxicity for up to 7 days. We also tested eNAT and AVL buffers directly and by dilution on Vero E6 cell lines without prior purification to confirm cytotoxicity in the absence of any purification steps, which showed cytotoxicity until 1:1000 dilution.

Inactivation of SARS-CoV-2 treated with eNAT

Viral inactivation with eNAT was explored in two different approaches; 1) by spiking the virus directly to the eNAT, simulating a swab sample that is placed into a transport media; and 2) by diluting a clinical sample such as saliva in eNAT, simulating a self-collected sample transport scenario. For the first approach, 100µl of the SARS-CoV-2 virus culture (8×10⁶ PFU/ml) was added to 2ml of eNAT, mixed and incubated for 0, 1, 2, 5, 10 and 15 min at room temperature. After incubation, the entire sample was processed using Pierce 4ml DRSC to remove cytotoxic components from eNAT. For the second approach, one-ml of confirmed COVID-19 negative saliva was spiked with 100 µl of SARS-CoV-2 (3×10⁶ PFU/ml) and then added to eNAT at 1:1 and 1:2 sample to eNAT ratio. The samples were incubated at room temperature for 10, 15 and 30 min for the 1:1 ratio and 5, 10, 15 min for the 1:2 ratio. Samples were then processed with the DRSC columns as described above. We performed two negative controls for both approaches. The first negative control consisted of 100 µl of virus free DMEM, which was added to 2 ml of eNAT at both 1:1 and 1:2 ratio; the second negative control consisted of 100 µl of the SARS-CoV-2 virus that was spiked into 400 µl of AVL buffer (Qiagen, Germantown, MD) and then heated to 92°C for 15 min to inactivate the virus. As a positive control, 100 µl of SARS-CoV-2 was spiked into 2 ml of DMEM. Positive control samples were also assessed before and after DRSC purification to determine viral loss during this process. All controls were performed in either duplicate or triplicate for each experiment.

Calculating eNAT sterilizing activity

Viral cytopathic effect (CPE) was determined in all samples by both direct infection in Vero E6 cell lines in 6-well plates and TCID50 assay by serial diluting of the samples on 96-well plates. For TCID50 assay, samples were diluted ten-fold in DMEM+2%FBS and titers were calculated by Reed & Muench method [17]. Viral titer reduction was determined by subtracting the viral titer for the treated samples from the untreated samples. For serial passaging of the samples, each 2 ml replicate of the DRSC column purified sample was added into 4 different wells (500 µl of the sample in each well) in a 6-well plate and incubated at 37°C/5% CO₂ for up to 14 days, with two passages every 5 to 7 days. The plates were checked daily under an inverted microscope for the presence of CPE. All samples were also tested by RT-PCR at days 7 and 14 of serial passaging using the Xpert Xpress SARS-CoV-2 test (Xpert, Cepheid, Sunnyvale, CA). The Xpert test reports amplification of sequences of the envelope (E) and nucleocapsid (N2) genes. Positive results were indicated by the detection of either the N2 target or both E and N2 targets.

Integrity of SARS-CoV-2 RNA in eNAT

The stability of SARS-CoV-2 RNA in eNAT was evaluated for a period of 7 days. Negative saliva samples were spiked with SARS-CoV-2 virus at 5X the LOD (0.05 PFU/ml) previously established for nasopharyngeal (NP) matrix using the Xpert test [18]. Samples were either swabbed and/or diluted 1:2 in eNAT. All samples were stored at three different temperatures (4°C, 28°C and 35°C) and viral RNA was measured at different time points (0h, 4h, 24h, 48h and 168 h) using the Xpert test.

Statistical analysis

Standard statistical analyses (average, standard deviation, and ANOVA) were performed using GraphPad Prism 8.4.3 for Windows.

Removal of basal cytotoxicity

Both eNAT and AVL buffers are cytotoxic to Vero E6 cell lines when used directly. We explored four different methods of purification as listed in Table 1. Microscopic observation of the Vero E6 cell lines in a 6-well plate revealed that the buffers purified through DRSC columns and Slide-A-Lyzer G2 dialysis cassettes did not show any cytotoxic effect to Vero E6 cells for up to 7 days. However, the filtrates from PD 10 and Amicon ultra columns were cytotoxic within 24 hours (Table 1).

Inactivation of SARS-CoV-2 with eNAT

eNAT, a guanidine-thiocyanate based sample transport medium is claimed to maintain the integrity of nucleic acids for long periods (https://www.copanusa.com/sample-collection-transport-processing/enat/). We evaluated the ability of eNAT as a transport media to inactivate SARS-CoV-2 directly (simulating swab samples) or when diluted with saliva. The virus was added directly to eNAT at the final concentration of 8×10⁵ PFU/ml, incubated for 0, 1, 2, 5, 10 and 15 min and filtered using DRSC columns. Vero E6 cell lines were infected with the flow through from these samples and observed for cytopathic effect for up to 14 days with two passages. All test samples and controls were processed and tested on Vero E6 cells in the same manner. We found that the negative controls did not cause any CPE while a 100 µl positive control containing 8×10⁶ PFU/ml of SARS-CoV-2 resulted in high CPEs within 48-72 hours of infection in Vero E6 cells. After 14 days of incubation and two passages, both replicates of the test samples incubated in eNAT for 0 min produced CPEs and were positive for SARS-CoV-2 by RT-PCR with an average N2 cycle threshold (Ct) 37.4±1.6 (Table 2). We did not observe any visible CPE after 1 min of incubation in eNAT; however, the RT-PCR assay was positive in 1 out of 2 replicates (Ct 37.4). Extending eNAT incubation to 2 min through 15 mins eliminated both CPE and any RT-PCR positivity, demonstrating a >5.6 log₁₀ PFU/ml reduction in the viral load (Table 2).

We further explored the ability of eNAT to inactivate SARS-CoV-2 when diluted in a sample such as saliva. We spiked SARS-CoV-2 (3×10⁶ PFU/ml) into SARS-CoV-2 negative saliva and then incubated the samples with eNAT at 1:1 and 1:2 (sample to eNAT) ratios for different time points at room temperature. After 14 days of incubation and 2 passages, eNAT alone and AVL buffer negative controls, maintained cell integrity without any visible CPEs and positive control showed CPEs within 48 hours (N2-Ct=13.8; Table 3). Although we did not observe any CPEs under any test conditions, the 1:1 saliva/eNAT mixtures were found to be SARS-CoV-2 positive by RT-PCR with N2-Ct >40 in all replicates (3/3) after 10 and 15 min of incubation. Even after 30 min of incubation in eNAT, 2/3 samples were positive for SARS-CoV-2 by RT-PCR. However, the spiked saliva samples that were mixed with 1:2 ratios of eNAT appeared to be completely inactivated (calculated SARS-CoV-2 inactivation efficacy >5.6 log₁₀ PFU/ml) after as little as 5 min incubation with the eNAT.

Stability of SARS-CoV-2 RNA in eNAT

We evaluated the stability of the SARS-COV-2 RNA in saliva treated with eNAT over a range of storage times and temperatures. SARS-COV-2 virus was spiked into saliva samples at 5X the established NP LOD (0.05 PFU/ml) of the Xpert test, and the samples were added to eNAT either as swab samples or saliva/eNAT mixed at 1:2 ratio. The samples were stored at 4°C, 28°C and 35°C and were periodically tested for the presence of SARS-CoV-2 by RT-PCR after 0, 4, 24, 48 and 168 h (7 days) of storage. As shown in Fig. 1A, the RNA was stable for the swab samples stored in eNAT under all conditions as indicated by N2 gene cycle threshold (Ct) (P>0.05). In saliva samples diluted 1:2 in eNAT, the RNA was stable until 168 h at 4°C and for 48 h at 28°C (P>0.05, Fig. 1B). However, average N2-Ct increased by 3 Ct values at 28°C after 7 days (P=0.004), as well as a significant decrease in RNA in as little as 24 hours in samples incubated at 35°C (P=0.01). The RNA detection rate remained at 100% positive rate for all samples with very low viral load, through all tested conditions despite the increase in assay Ct values over time and increased temperature.

• Download figure
• Open in new tab

Fig. 1.

Stability of SARS-CoV-2 RNA in a swab of saliva mixed with eNAT (A) or saliva diluted 1:2 with eNAT (B). Saliva samples were spiked with SARS-CoV-2 virus at 5X the LOD (0.005 PFU/ml) and maintained at 4°C, 28°C (room temperature) and 35°C. The samples were tested for SARS-CoV-2 RNA by RT-PCR at 0, 4, 24, 48 and 168 hours. N2 gene cycle threshold (Ct) values are shown. Four replicates were performed for each condition and results are expressed as mean±SD. ns-not statistically significant. P<0.05 is considered statistically significant.